Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands

Background: Immunocompromising conditions and advanced age (>= 65 years) are associated with a high risk for invasive pneumococcal disease (IPD). We investigated the risk and outcomes of IPD in adults with underlying conditions in the post-PCV7 era in The Netherlands. Methods: IPD data from 2008 to 2012 was obtained from the national pneumococcal surveillance system, covering 25% of the Dutch population. Population estimates of underlying conditions were derived from the primary care data (2012). IPD incidence in adults with immunocompromising conditions (high risk group) and non-immunocomp... Mehr ...

Verfasser: Wagenvoort, Gertjan H. J.
Knol, Mirjam J.
de Melker, Hester E.
Vlaminckx, Bart J.
van der Ende, Arie
Rozenbaum, Mark H.
Sanders, Elisabeth A. M.
Dokumenttyp: Artikel
Erscheinungsdatum: 2016
Reihe/Periodikum: Wagenvoort , G H J , Knol , M J , de Melker , H E , Vlaminckx , B J , van der Ende , A , Rozenbaum , M H & Sanders , E A M 2016 , ' Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands ' , Vaccine , vol. 34 , no. 3 , pp. 334-340 . https://doi.org/10.1016/j.vaccine.2015.11.048
Schlagwörter: Streptococcus pneumoniae / Pneumococcal conjugate vaccine / Invasive pneumococcal disease / Surveillance / Clinical outcome / Comorbidity / Serotypes / 23-VALENT POLYSACCHARIDE VACCINE / CONJUGATE VACCINE / STREPTOCOCCUS-PNEUMONIAE / CHILDREN / IMPACT / ENGLAND / IMMUNIZATION / FRAILTY / BURDEN / COHORT
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27602161
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/d62b9dec-8abb-4b42-9330-6553175dd879

Background: Immunocompromising conditions and advanced age (>= 65 years) are associated with a high risk for invasive pneumococcal disease (IPD). We investigated the risk and outcomes of IPD in adults with underlying conditions in the post-PCV7 era in The Netherlands. Methods: IPD data from 2008 to 2012 was obtained from the national pneumococcal surveillance system, covering 25% of the Dutch population. Population estimates of underlying conditions were derived from the primary care data (2012). IPD incidence in adults with immunocompromising conditions (high risk group) and non-immunocompromising comorbidities (medium risk group) were compared to the "normal risk group" without diagnosed comorbidities. Case-fatality and ICU admission in the different risk groups was analyzed by logistic regression. Serotype specific propensities to affect high risk group IPD patients were calculated. Results: Adults with a high risk condition have a 18-fold (95% CI 15.6-21.2) and 3-fold (95% CI 2.6-3.9) higher risk compared to the normal risk group for IPD at age 18-64 years and 65 years and older, respectively. In case of a medium risk condition, the risk is 5-fold (95% CI 4.3-5.7) and 2-fold (95% CI 1.9-2.6) higher in age groups 18-64 and >= 65 years old. Likewise, IPD patients with a high or medium risk condition have a higher case-fatality (after adjustment for age, odds ratio: 2-fold (95% CI 1.5-3.5) and 1.4-fold (95% CI 1.0-2.1), respectively). Several serotypes (e.g. 6A, 6B, 23A and 23B) are associated with a significantly higher propensity to cause disease in high risk patients. Conclusions: The risk for IPD and death in the post-PCV7 era has remained considerably high in adults and elderly with underlying conditions. The identification of serotypes with a high propensity to affect risk groups can be important for selecting (future) vaccine serotypes. (C) 2015 Elsevier Ltd. All rights reserved.